Journal article
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
Gynecologic Oncology, Vol.138(3), pp.507-512
09/2015
DOI: 10.1016/j.ygyno.2015.07.018
PMCID: PMC4642817
PMID: 26186911
Abstract
Cediranib is a multi-tyrosine kinase inhibitor targeting vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors. This phase II study was conducted to assess activity and tolerability of single-agent cediranib in recurrent/persistent endometrial cancer. Eligible patients had recurrent or persistent endometrial cancer after receiving one or two prior cytotoxic regimens, measurable disease, and Gynecologic Oncology Group (GOG) performance status of ≤2 (≤1 if two prior cytotoxic regimens given). Cediranib 30mg orally daily for a 28daycycle was administered until disease progression or prohibitive toxicity. Microvessel density (MVD) was measured in tumor tissue from initial hysterectomy specimens and correlated with clinical outcome. Primary endpoints were tumor response and surviving progression-free for six months without subsequent therapy (6-month event-free survival [EFS]). Of 53 patients enrolled, 48 were evaluable for cediranib efficacy and toxicity. Median age was 65.5years, 52% of patients had received prior radiation, and 73% of patients received only one prior chemotherapy regimen. A partial response was observed in 12.5%. Fourteen patients (29%) had six-month EFS. Median progression-free survival (PFS) was 3.65months and median overall survival (OS) 12.5months. No grade 4 or 5 toxicities were observed. A trend towards improved PFS was found in patients whose tumors expressed high MVD. Cediranib as a monotherapy treatment for recurrent or persistent endometrial cancer is well tolerated and met protocol set objectives for sufficient activity to warrant further investigation. MVD may be a useful biomarker for activity. •Cediranib is an active multi-tyrosine kinase inhibitor in uterine cancer.•Cediranib for recurrent uterine cancer had a 33% six-month progression free survival.•Cediranib is a safe and well-tolerated oral treatment for recurrent uterine cancer.
Details
- Title: Subtitle
- A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
- Creators
- David Bender - Gynecologic Oncology Division, University of Iowa, Gyn/Onc Division, Iowa City, IA 52242, United StatesMichael W Sill - NRG Oncology Statistics & Data Management Center, Roswell Park Cancer Institute, Buffalo, NY 14263, United StatesHeather A Lankes - NRG Oncology Statistics & Data Management Center, Roswell Park Cancer Institute, Buffalo, NY 14263, United StatesHenry D Reyes - Gynecologic Oncology Division, University of Iowa, Gyn/Onc Division, Iowa City, IA 52242, United StatesChristopher J Darus - Division of Gynecologic Oncology, Maine Medical Center, Scarborough, ME 04101, United StatesJames E Delmore - University of Kansas School of Medicine, Wichita CCOP, Wichita, KS 67208, United StatesJacob Rotmensch - Division of Gynecologic Oncology, Rush-Presbyterian St. Lukes Medical Center, Chicago, IL 60612, United StatesHeidi J Gray - Dept. of OB/GYN, University of Washington, Seattle, WA 98195, United StatesRobert S Mannel - Dept. of OB/GYN, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United StatesJeanne M SchilderMark I Hunter - Ellis Fischel Cancer Center, Columbia, MO 65203, United StatesCarolyn K McCourt - Dept. of Oncology, Women & Infants Hospital, Providence, RI 02905, United StatesMegan I Samuelson - Gynecologic Oncology Division, University of Iowa, Gyn/Onc Division, Iowa City, IA 52242, United StatesKimberly K Leslie - Gynecologic Oncology Division, University of Iowa, Gyn/Onc Division, Iowa City, IA 52242, United States
- Resource Type
- Journal article
- Publication Details
- Gynecologic Oncology, Vol.138(3), pp.507-512
- DOI
- 10.1016/j.ygyno.2015.07.018
- PMID
- 26186911
- PMCID
- PMC4642817
- NLM abbreviation
- Gynecol Oncol
- ISSN
- 0090-8258
- eISSN
- 1095-6859
- Publisher
- Elsevier Inc
- Grant note
- 1 U10 CA180822 / NRG Oncology U24 CA114793 / GOG Tissue Bank Barbara Beach Fund CA 27469 / GOG Core Laboratory for Receptors and Targets CA 37517 / GOG Statistical and Data Center U10CA180868 / NRG Operations R01-CA099908 / K. Leslie CA 27469 / National Cancer Institute (http://dx.doi.org/10.13039/501100002387)
- Language
- English
- Date published
- 09/2015
- Academic Unit
- Pathology; Obstetrics and Gynecology
- Record Identifier
- 9983931826302771
Metrics
42 Record Views